Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 16, 2026

A Macrophage-Tumor Spheroid Co-Invasion Assay
09:01

A Macrophage-Tumor Spheroid Co-Invasion Assay

Published on: January 24, 2025

Flipping the script on macrophages in leiomyosarcoma.

Badreddin Edris1, Kipp Weiskopf, Irving L Weissman

  • 1Department of Pathology; Stanford University School of Medicine; Stanford, CA USA ; Department of Genetics; Stanford University School of Medicine; Stanford, CA USA.

Oncoimmunology
|November 22, 2012
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolation of postnatal human neural stem cells.

bioRxiv : the preprint server for biology·2026
Same author

Xenophagocytosis blockade enhances interspecies chimerism.

Cell·2026
Same author

Somatic mutations reveal the ontogeny of human microglia.

bioRxiv : the preprint server for biology·2026
Same author

Polyclonal regeneration of mouse bone marrow endothelial cells after irradiative conditioning.

Cell reports·2026
Same author

Electrical stimulation promotes longevity and regeneration in a colonial chordate.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Scalable single-cell total RNA sequencing unifies coding and noncoding transcriptomics.

Nature biotechnology·2026

Targeting CD47 on leiomyosarcoma (LMS) tumor cells with antibodies enables macrophages to engulf and eliminate cancer cells. This approach shows promise for treating LMS by preventing tumor growth and metastasis.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • Macrophages play a crucial role in promoting the growth of leiomyosarcoma (LMS), a rare and aggressive soft-tissue cancer.
  • The CD47 protein on the surface of LMS cells interacts with the signal regulatory protein α (SIRPα) on macrophages, inhibiting phagocytosis (cellular engulfment).

Purpose of the Study:

  • To investigate the therapeutic potential of targeting the CD47-SIRPα axis in leiomyosarcoma.
  • To evaluate the efficacy of anti-CD47 monoclonal antibodies (mAbs) in overcoming macrophage-mediated immune evasion in LMS.

Main Methods:

  • Utilized anti-CD47 monoclonal antibodies (mAbs) in a preclinical model of leiomyosarcoma.
  • Assessed the ability of macrophages to phagocytose LMS cells following treatment with anti-CD47 mAbs.

More Related Videos

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

Related Experiment Videos

Last Updated: May 16, 2026

A Macrophage-Tumor Spheroid Co-Invasion Assay
09:01

A Macrophage-Tumor Spheroid Co-Invasion Assay

Published on: January 24, 2025

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

  • Evaluated the impact of anti-CD47 mAb treatment on tumor growth and metastasis.

    • Main Results:

    • Anti-CD47 mAbs successfully enabled macrophages to engulf and eliminate leiomyosarcoma cells.
    • Treatment with anti-CD47 mAbs significantly inhibited tumor growth.
    • Metastatic spread of leiomyosarcoma was reduced following anti-CD47 mAb therapy.

    Conclusions:

    • The CD47-SIRPα signaling pathway is a critical mechanism of immune evasion in leiomyosarcoma.
    • Anti-CD47 monoclonal antibodies represent a viable targeted immunotherapy strategy for LMS.
    • This approach holds promise for preventing leiomyosarcoma progression and metastasis.